Anivive’s GC376 Reduces COVID-19 Replication, Shows Potential as New Post-Infection Treatment

The PNAS article “Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection” describes a study that shows that mice with fatal SARS-CoV-2 infections have a decreased and improved viral load Survival was shown when treated with deuterated variants of GC376, an antiviral drug developed by Anivive Lifesciences.

All coronaviruses, including SARS-CoV-2, contain a protease that is responsible for replicating the virus. GC376 is a protease inhibitor designed to block the replication process and stop the virus from spreading.

For the study, SARS-CoV-2 infected mice that developed pulmonary pathology similar to severe COVID-19 in humans were given a number of deuterated variants of GC376 to assess antiviral activity against SARS-CoV-2. Treatment was started 24 hours after infection. Study results show that GC376 has excellent therapeutic efficacy as an antiviral agent against SARS-CoV-2.

“We welcome more conclusive evidence that GC376 shows potent activity against the major protease 3CLpro in SARS-CoV-2 with a high therapeutic index,” said Anivive Chief Medical Officer, David Bruyette. “GC376 continues to show in vitro and in vivo activity against many human and animal coronaviruses.”

Anivive, a pet health-focused biotechnology company, has been developing GC376 since 2018 to treat a deadly cat disease caused by a coronavirus. Feline infectious peritonitis is the leading cause of death in kittens and kittens, affecting up to 1 in 300 cats worldwide.

That University of California at Davis Field tests conducted on the use of GC376 in cats with FIP. GC376 reversed symptoms within 48 hours with no significant side effects.

GC376 has the potential to become a one health drug offering therapeutic benefits to both pets and humans. Anivive has filed a pre-investigation drug application with the Food and Drug Administration to evaluate GC376 as a treatment for COVID-19 following infection in humans.

“We hope to leverage existing animal labor to accelerate the availability of effective COVID-19 therapeutics to humans,” said Anivive CEO, Dylan Balsz. “With this additional exciting research, we look forward to speaking with the FDA and moving forward toward a clinical trial.”

About GC376

GC376 is a broad-spectrum antiviral drug being developed by Anivive Lifesciences for therapeutic use in animals and humans. GC376 is a premium small molecule protease inhibitor and blocks 3CLpro, a protease common to many coronaviruses, with high therapeutic efficacy. Anivive licensed exclusive worldwide patent rights to GC376 from Kansas State University.

About Anivive

Anivive reinvents the drug development process in pet pharma. Our proprietary software accelerates the delivery of new, affordable pet treatments.

Supported by over $ 45 million In the area of ​​seed funding, Anivive has received conditional approval for LAVERDIA ™ -CA1 (Verdinexor), the first oral tablet for the treatment of canine lymphoma, and has created a dedicated sales team to assist veterinarians. Anivive’s pipeline includes over 8 world-class pharmaceuticals, biologics and vaccines. For more information on how we meet unmet pet needs, please visit anivive.com.

SOURCE Anivive Lifesciences Inc.

related links

https://www.anivive.com